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Abstract
Background: Staphylococcus aureus and S. epidermidis biofilms differ in structure, growth and
regulation, and thus the high-throughput method of evaluating biofilm susceptibility that has been
published for S. epidermidis cannot be applied to S. aureus without first evaluating the assay's
reproducibility and reliability with S. aureus biofilms.
Methods:  Staphylococcus aureus biofilms were treated with eleven approved antibiotics,
lysostaphin, or Conflikt®, exposed to the oxidation reduction indicator Alamar blue, and reduction
relative to untreated controls was determined visually and spectrophotometrically. The minimum
biofilm inhibitory concentration (MBIC) was defined as ≤ 50% Alamar blue reduction and a purple/
blue well 60 min after the addition of Alamar blue. Because all of the approved antibiotics had
MBICs >128 μg/ml (most >2048 μg/ml), lysostaphin and Conflikt®, with relatively low MBICs, were
used to correlate Alamar blue reduction with 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide (XTT) reduction and viable counts (CFU/ml) for S. aureus ATCC
29213 and three clinical isolates. Alamar blue's stability and lack of toxicity allowed CFU/ml to be
determined from the same wells as Alamar blue absorbances.
Results: Overall, Alamar blue reduction had excellent correlation with XTT reduction and with
CFU/ml. For ATCC 29213 and two clinical isolates treated with lysostaphin or Conflikt®, Alamar
blue reduction had excellent correlation with XTT reduction (r = 0.93-0.99) and with CFU/ml (r
= 0.92-0.98). For one of the clinical isolates, the results were moderately correlated for Conflikt®
(r = 0.76, Alamar blue vs. XTT; r = 0.81, Alamar blue vs. CFU/ml) and had excellent correlation for
lysostaphin (r = 0.95, Alamar blue vs. XTT; r = 0.97, Alamar blue vs. CFU/ml).
Conclusion: A reliable, reproducible method for evaluating biofilm susceptibility was successfully
applied to S. aureus biofilms. The described method provides researchers with a simple, nontoxic,
relatively inexpensive, high throughput measure of viability after drug treatment. A standardized
biofilm Alamar blue assay should greatly increase the rate of discovery of S. aureus biofilm specific
agents.
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Background
In the U.S., one million nosocomial infections each year
are related to infections caused by biofilms on implanted
devices [1]. Mortality for septicemias associated with vas-
cular devices ranges from 20-40% [2], and intravenous
catheters are the most common cause of nosocomial sep-
ticemia [3]. Staphylococcus aureus and S. epidermidis are the
most common infectious agents associated with foreign
device infections [4-6], and are found in biofilms in a
wide range of other diseases, including endocarditis and
osteomyelitis [7].
In vitro surface-associated and in vivo device-associated
bacterial biofilms are generally quite resistant to antibiotic
treatment [7,8]. Despite decades of research in this area,
treatment options are limited. A factor contributing to this
unmet need is the lack of a standardized method for deter-
mining the drug susceptibility of bacterial biofilms. Sev-
eral methods are available, but are limited by long
processing times, incompatibility with high throughput,
expensive reagents or equipment, or the method measures
mass instead of viability [9-13]. A simple high-throughput
assay that measures viability has been standardized for S.
epidermidis [14] and Candida albicans [15]. This colorimet-
ric Alamar blue (AB) assay was reliable, reproducible and
had good to excellent correlation with two other biofilm
susceptibility methods, 2,3-bis(2-methoxy-4-nitro-5-sul-
fophenyl)-2H-tetrazolium-5-carboxanilide (XTT) reduc-
tion and viable counts (CFU/ml) for four strains of S.
epidermidis.
Alamar blue has been used extensively in mammalian cell
culture cytotoxicity assays and planktonic bacterial and
fungal susceptibility assays, and is a simple, one-step pro-
cedure, in which metabolic activity results in the chemical
reduction of AB. Alamar blue is reduced by FMNH2,
FADH2, NAHD, NADPH and the cytochromes (product
literature, Trek Diagnostic Systems). Alamar blue both flu-
oresces and changes color in response to chemical reduc-
tion, and the extent of the conversion is a reflection of cell
viability (product literature, Trek Diagnostic Systems).
Continued growth maintains a reduced environment
while inhibition of growth maintains an oxidized envi-
ronment. Alamar blue is water soluble, so the washing/
fixation/extraction steps required in other commonly
used cell proliferation assays are not required. Data may
be collected with the naked eye, or for increased sensitiv-
ity, with either fluorescence-based or absorbance-based
instruments. Alamar blue is also nontoxic to both the
investigator and to the cells of interest, so it is safe to work
with, easily disposed of and less likely to interfere with
normal metabolism in test cells. In addition, AB is stable,
so long incubations are possible, as are kinetic studies.
There are numerous differences in biofilm structure,
growth and regulation in S. aureus and S. epidermidis [16-
18]. Biofilms from different species of Candida also differ
in structure and growth [19,20], so the colorimetric XTT
susceptibility assay must be standardized for each species
[21]. The high-throughput method of evaluating biofilm
susceptibility that has been published for S. epidermidis
cannot be applied to S. aureus without first evaluating the
assay's reproducibility and reliability with S. aureus bio-
films.
Methods
Strains
Staphylococcus aureus ATCC 29213 (wound isolate) and
three clinical isolates (520009, 520016, 520020; Arizona
Department of Health Services, Phoenix, AZ) were main-
tained on Mueller-Hinton agar (MHA) at 35°C. To con-
firm biofilm formation, S. aureus ATCC 29213, a known
biofilm former [10], and the three clinical isolates were
grown on glass and polystyrene for 24 and 48 h at 35°C
without shaking, stained with Congo red, rinsed, drained
and adhesion relative to 17 other clinical isolates was
ranked.
Antimicrobial agents
Clindamycin, bacitracin, vancomycin, ciprofloxacin, gen-
tamicin, rifampin, nitrofurazone and enrofloxacin were
obtained from ICN. Ceftriaxone, penicillin and oxacillin
were from Sigma. Clindamycin, rifampin, nitrofurazone
and enrofloxacin were dissolved in sterile dimethyl sul-
foxide (DMSO). The remaining antibiotics and lys-
ostaphin were dissolved in sterile H2O. Conflikt® (Decon
Laboratories Inc.) was used as received.
Alamar blue biofilm susceptibility assay
The AB biofilm susceptibility assay and calculation of the
percent reduction of AB were performed as described for
S. epidermidis [14]. Alamar blue (Trek Diagnostic Sys-
tems), which is blue-colored in its oxidized state, is
reduced in metabolically active cells to the pink colored
resorufin. Alamar blue was aliquoted and stored at -80°C.
Prior to each experiment, AB was brought to room tem-
perature and vortexed. Exposure of AB to light was mini-
mized throughout experiments. Isolated colonies from
18-22 MHA plates were used to prepare inocula. Assays
were performed in flat bottom, polystyrene, non-tissue
culture treated microtiter plates containing 5 × 105 CFU/
ml in MHIIB media, with final well volumes of 100 μl.
Plates were incubated at 37°C without shaking. Two fold-
dilutions of drugs in cation-adjusted MHIIB were pre-
pared external to the plates. After 24 h, 50 μl was removed
from all experimental and control wells, and 50 μl of the
appropriate drug dilution added. Biofilms were exposed
to drugs for 20 h at 37°C without shaking. After 20 h, 5 μl
AB was added to wells (105 μl total volume), the platesAnnals of Clinical Microbiology and Antimicrobials 2009, 8:28 http://www.ann-clinmicrob.com/content/8/1/28
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shaken gently and incubated for 1 h at 37°C. Plates were
gently shaken again and absorbance at 570 nm and 600
nm obtained in a Perkin Elmer Wallac Victor3 microplate
reader. For experiments with multiple time points, plates
were kept in a 37°C incubator between absorbance read-
ings. Controls included media alone, media plus AB,
media plus AB plus drug dilution, and cells plus media
plus AB. Percent reduction of AB was calculated using the
manufacturer's formula, with replacement of their nega-
tive control, which contains only media plus AB, with a
more robust negative control, media plus AB plus a drug
concentration equal to each experimental well:
where,
εox = molar extinction coefficient of Alamar blue oxidized
form (blue)
εred = molar extinction coefficient of Alamar blue reduced
form (pink)
A = absorbance of test wells
A' = absorbance of negative control well
λ1 = 570 nm
λ2 = 600 nm
The AB minimum biofilm inhibitory concentration
(MBIC) was defined as the lowest drug concentration
resulting in ≤ 50% reduction of AB and a purple/blue well
60 min after the addition of AB [14]. Assays were per-
formed at least twice, and the average % reduction used to
determine the AB MBIC.
Alamar blue planktonic susceptibility assay
Planktonic susceptibility testing of S. aureus was per-
formed by the CLSI reference broth microdilution assay
(BMA) [22] as previously described [14]. Assays were per-
formed at least twice, and the average % reduction used to
determine the MIC. The AB MIC was defined as the lowest
drug concentration resulting in ≤ 50% reduction of AB
and a purple/blue well 60 min after the addition of AB
[14].
Biofilm 2,3-bis(2-methoxy-4-nitro-5-sulfophenyl)-2H-
tetrazolium-5-carboxanilide (XTT) reduction assay
The biofilm XTT reduction assay and calculation of per-
cent formazan production were performed exactly as
described for S. epidermidis [14].
Biofilm CFU/ml assay
CFU/ml were obtained from the same wells used to
obtain biofilm AB absorbances as previously described
[14].
Correlation of Alamar blue reduction to XTT reduction 
and CFU/ml
For correlation experiments, AB, XTT and CFU/ml assays
were performed the same day using a single inoculum.
Experiments were repeated at least twice. Pearson's two-
tailed correlations were calculated with Prism 4 software
using averaged data from the entire range of drug concen-
trations.
Results
When the relative adhesion of 20 S. aureus clinical isolates
and biofilm positive ATCC 29213 was scored, S. aureus
ATCC 29213 and clinical isolates 520009, 520016 and
520020 ranked medium to high on both glass and poly-
styrene (three isolates were biofilm-negative on both sub-
strates; the remaining isolates ranked medium to high on
one or both substrates).
In order to make the assay as efficient as possible, the
shortest possible AB reduction endpoint was determined
as for S. epidermidis [14]. Twenty-four hour S. aureus bio-
films were treated for 20 h with ciprofloxacin, lysostaphin
or Conflikt®. Alamar blue was then added and absorbance
determined 30, 60 and 90 min after the addition of AB.
The susceptibility pattern was clear at 60 min (data not
shown), just as with S. epidermidis [14], so this time point
was chosen as the endpoint for absorbance readings in all
experiments.
Prior to determining biofilm susceptibility, MICs for a
variety of antibiotics with different mechanisms of action
were determined for planktonic-grown S. aureus ATCC
29213 (Table 1). Turbidometric and AB MICs for plank-
tonic grown strains were identical or within one twofold
dilution (data not shown). MICs and MBICs were defined
as the lowest drug concentration resulting in ≤ 50% reduc-
tion of AB, and in the case of noncolored compounds, a
purple/blue well 60 min after the addition of AB (for
colored compounds, AB reduction can only be deter-
mined spectrophotometrically). Alamar blue MBICs
increased at least five-fold relative to planktonic AB MICs
(Table 1), consistent with previous reports of many-fold
increases in drug resistance of biofilm vs. planktonic-
grown strains [7]. Even at doses of 2048 μg/ml, S. aureus
ATCC 29213 biofilms were resistant to all antibiotics
tested (Table 1). Nitrofurazone and ciprofloxacin could
not be tested at doses higher than indicated (Table 1)
because they precipitate at 512 μg/ml and 256 μg/ml,
respectively.
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As no antibiotics inhibited S. aureus ATCC 29213 bio-
films, we investigated an enzyme with reported activity
against S. aureus biofilms, and a widely used disinfectant.
Lysostaphin is an endopeptidase that cleaves the cross-
linking pentaglycine bridges of the cell wall of staphyloco-
cci [23]. At low concentrations, lysostaphin kills S. aureus
biofilms and, in addition, disrupts the biofilm matrix
[24]. Coating catheters with lysostaphin prevents catheter
colonization [25]. Conflikt® (Decon) detergent disinfect-
ant is a quaternary ammonium based disinfectant. Lys-
ostaphin and Conflikt® were effective against biofilms at
much lower doses than the antibiotics (Figs. 1, 2). The AB
MBIC for ATCC 29213 with lysostaphin, for example, was
4 μg/ml (Fig. 1A), and for Conflikt® was 0.625% (Fig. 2A).
Planktonic MICs for the four strains ranged from 2-4 μg/
ml for lysostaphin, and from 0.039-0.078% for Conflikt®.
To help validate the described AB method for S. aureus
biofilm susceptibility, AB assays were performed in paral-
lel with XTT reduction assays, and CFU/ml were obtained
from the same wells as AB absorbances. Reduction of
tetrazolium salts, for e.g. XTT, is a common method of
determining microbial cell viability [26], but XTT has sev-
eral drawbacks, including toxicity. Alamar blue is stable
and nontoxic, so unlike other metabolic assays, it is possi-
ble to plate directly out of wells over long periods for
determination of viable cell counts. Similarly, in the CLSI
planktonic assay [22], minimum bactericidal concentra-
tions (MBCs) are obtained from the same wells as MICs.
Biofilms of S. aureus ATCC 29213 and three clinical iso-
lates were established overnight and treated with lys-
ostaphin or Conflikt®  for 20 h. Alamar blue or XTT/
menadione was added, and after 1 h, absorbances were
obtained and wells scraped for dilution-plating (Figs. 1,
2). There was typically a small amount of biofilm growth
from 24 h (Figs. 1, 2 arrows) to 44 h (Figs. 1, 2, 0 μg/ml).
As evident in Figures 1 and 2, the AB MBIC corresponds to
a many log-fold reduction in CFU/ml. These results sup-
port the hypothesis that metabolic activity is a useful
measurement of viability, and that the AB assay is an
extremely sensitive method.
Pearson's two-tailed correlation coefficients were calcu-
lated from the data in Figures 1 and 2. With the exception
of Conflikt®-treated S. aureus 520020, where AB vs. XTT
and AB vs. CFU/ml were moderately correlated (r = 0.76,
r = 0.81, respectively) [Table 2], AB had excellent correla-
tion with XTT and CFU/ml (Table 2).
Discussion
Together, S. aureus and S. epidermidis are responsible for
most implant and prosthetic device infections. As such,
development of a standardized method to assess drug sus-
ceptibility of biofilms from both species is critical. An
automated microtiter plate assay was recently described
for susceptibility testing of S. aureus biofilms [27]. How-
ever, the assay was based on crystal violet staining, which
does not measure viability. A high-throughput method
employing AB, which does measure viability, has been
described for S. epidermidis [14]. Recently, Peeters et al.
[26] compared a variety of methods for quantifying bio-
films (no susceptibility testing), and found the fluorescent
AB assay to be very reliable for quantifying S. aureus bio-
films. Alamar blue reduction data can be collected with
the naked eye, or for increased sensitivity, with either flu-
orescence-based or absorbance-based instruments.
Because absorbance-based instruments can be found in
most laboratories, we evaluated the applicability of the AB
method for susceptibility testing of S. aureus biofilms
using absorbance. The biofilms produced by the four S.
aureus isolates were so resistant to conventional antibiot-
ics that lysostaphin and Conflikt® had to be employed for
correlation studies.
Although biofilm structure, growth and regulation in S.
aureus  and S. epidermidis is not equivalent [16-18], we
Table 1: Alamar blue MICs and MBICs* of antibiotics against planktonic- and biofilm-grown S. aureus ATCC 29213
Drug Planktonic MIC (μg/ml) Biofilm MBIC (μg/ml)
gentamicin 0.25 >2048
clindamycin 16 >2048
bacitracin 32 >2048
nitrofurazone 8 >256
vancomycin 0.5 >2048
ciprofloxacin 0.25 >128
enrofloxacin 0.0625 >2048
ceftriaxone 2 >2048
penicillin 0.5 >2048
oxacillin 0.0625 >2048
rifampin <0.0008 >2048
*MIC or MBIC defined as the lowest drug concentration resulting in ≤50% reduction of AB (average of two experiments) and a purple/blue well 60 
min after addition of AB. MBICs for nitrofurazone and rifampin were only determined using the ≤50% reduction of AB criterion, as these antibiotics 
are colored at high doses.Annals of Clinical Microbiology and Antimicrobials 2009, 8:28 http://www.ann-clinmicrob.com/content/8/1/28
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have demonstrated that the AB assay is a reliable, repro-
ducible method of evaluating biofilm drug susceptibility
for both species [present study and [14]]. The standardiza-
tion and correlation results presented here suggest that
this method has promise for S. aureus biofilm susceptibil-
ity testing, but evaluation against a large panel of S. aureus
strains is warranted. Certainly, it would be useful to have
an effective conventional antibiotic for these larger stud-
ies, instead of widely reactive enzymes and detergents.
Should AB be developed as a standard method of biofilm
susceptibility testing, it would be useful to have consensus
on the definition of the MBIC. While this and a previous
study [14] used a value of ≤ 50% reduction of AB (which,
as demonstrated, corresponds to a many log-fold reduc-
tion in CFU), much more data from a variety of labs will
be necessary to define the most broadly applicable cutoff.
The benefits of AB over other methods of biofilm suscep-
tibility testing are numerous and include simplicity, rela-
tive cost, compatibility with high throughput, lack of
toxicity and importantly, AB measures viability, not sim-
ply mass. The major benefit of AB over XTT/menadione is
its lack of toxicity (menadione has human toxicity), and
the obvious benefit of AB over CFU/ml determination is
its simplicity. The AB biofilm assay can be performed in
any lab with a spectrophotometer, and is an excellent
Percent reduction of Alamar blue, percent formazan production and CFU/ml (right Y axis) for biofilms from four S. aureus  strains (A-D) treated for 20 h with two-fold dilutions of lysostaphin Figure 1
Percent reduction of Alamar blue, percent formazan production and CFU/ml (right Y axis) for biofilms from 
four S. aureus strains (A-D) treated for 20 h with two-fold dilutions of lysostaphin. Arrow, biofilm CFU/ml at 24 h 
(prior to drug treatment).Annals of Clinical Microbiology and Antimicrobials 2009, 8:28 http://www.ann-clinmicrob.com/content/8/1/28
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Percent reduction of Alamar blue, percent formazan production and CFU/ml (right Y axis) for biofilms from four S. aureus  strains (A-D) treated for 20 h with two-fold dilutions of Conflikt® Figure 2
Percent reduction of Alamar blue, percent formazan production and CFU/ml (right Y axis) for biofilms from 
four S. aureus strains (A-D) treated for 20 h with two-fold dilutions of Conflikt®. Arrow, biofilm CFU/ml at 24 h 
(prior to drug treatment).
Table 2: Pearson's correlation coefficients for lysostaphin and Conflikt®-treated S. aureus
Pearson's correlation coefficients with:
Lysostaphin Conflikt®
S. aureus strain Almar blue vs. XTT Alamar blue vs. CFU/ml Alamar blue vs. XTT Alamar blue vs. CFU/ml
ATCC 29213 0.96 0.96 0.98 0.95
520009 0.99 0.98 0.96 0.97
520016 0.99 0.93 0.93 0.92
520020 0.95 0.97 0.76 0.81Publish with BioMed Central    and   every 
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choice for high throughput labs. A standardized biofilm
AB assay should greatly increase the rate of discovery of
Staphylococcus biofilm specific agents.
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